🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. ja.ma/43beXGr

Welcome back Walker!

Flattered to be called an 🫁oncologist rather than surgeon UVA Cancer Center

#ESTS2025 off to a great start with Postgraduate Course contest- who doesn’t 🤍 a good game show? 🏆Team Asia for the win! 🥇

“This is not just a European meeting—it’s the World Meeting of Thoracic Surgery,” said Rene Horsleben Petersen during this morning’s Opening Remarks at #ESTS2025. With 1,660 participants from 75 countries, the global thoracic surgery community is truly united in Budapest.

Great discussion. Also brought up #patientpref Chat best case/worst case and most likely framework for discussing consent, treatment decisions. Highly relevant for daily practice but rarely taught.UVA Surgery UVA Cancer Center

Big congratulations to Resident Adishesh Narahari, MD, PhD, on receiving the prestigious David J. Sugarbaker Surgical Resident Investigator Award from AATS! Dr. Narahari's work is focused on lung ischemia-reperfusion injury. We're excited to see what's to come!

Elliot Servais, MD, FACS Drew Moghanaki Gavitt Woodard Yale Thoracic Surgery With regard to this, please take a look at an editorial coming out in AATS Journals from Marc Vimolratana and me. LN sampling/dissection SHOULD be nuanced and it is not that hard! jtcvs.org/article/S0022-…

Congratulations to the newly elected IASLC board members and newly elected president! IASLC is in great hands!!! 🙌🏽🎉🔥 Alex A. Adjei Triparna Sen (Sen-Lab) Mary Pasquinelli Isabelle Opitz Hidehito HORINOUCHI Clarissa Baldotto Narjust Florez, MD, FASCO Karen Kelly

Out now & open access in Nature Medicine concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone nature.com/articles/s4159… ! #LCSM 1/6

Presented at #ASCO25: In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN trial

The study I have most anticipated from #ASCO2025 CTSurgSocMedNetwork General Thoracic Surgical Club Remember control arm was the 🏆 from ESOPEC- so Rx arm has outperformed that!! Leaves CROSS in the dust for adeno.

Early Bird registration for #WCLC25 ends soon! 🕒 Join global experts in Barcelona, September 6–9, 2025, for this premier lung cancer event. 💸 #IASLC members get the best rates! 🔗 Register now: bit.ly/WCLC25Reg

Post #ASCO25, clinical T2N1 resectable adenocarcinoma NSCLC, no 🎯mutation, PDL1+ ≥ 1%, you would…? Is residual disease going to help dictate your postOP Rx? Role of ctDNA? PDL1? Patrick Forde Stephen V Liu, MD Narjust Florez, MD, FASCO Sandip Patel MD FASCO Eric K. Singhi, MD Bijoy Telivala Santhosh Ambika

Another 🔑result we’ve been waiting for as 🫁🔪CTSurgSocMedNetwork General Thoracic Surgical Club The Society of Thoracic Surgeons Global Thoracic Surgery Residents Association AATS Seems like we should start it as soon as EGFR + noted and continue Postop without interruption. IMO

We want to join the party too! General Thoracic Surgical Club

Beware: our formidable UVA Cardiothoracic Surgery team is gearing up! 💪🧠📚📖🙇🏻🙇🏽‍♀️🤺

C’mon UVA Cardiothoracic Surgery show us your answers 📝